Sarepta Therapeutics
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: Cambridge, Massachusetts, United States, North America
Region: Massachusetts
Country: US
Continent: North America
About
Sarepta Therapeutics is a global biotechnology company focused on precision genetic medicines to treat rare neuromuscular and central nervous system diseases. The company is advancing gene therapy and RNA-based approaches with an emphasis on Duchenne muscular dystrophy and related rare disorders, and is building manufacturing capacity to speed patient access. Headquartered with global operations, Sarepta collaborates across scientists, patients, and partners to bring transformative therapies to underserved populations.
Sarepta Therapeutics develops and commercializes precision genetic medicines for rare neuromuscular and central nervous system diseases. The company utilizes RNA-targeted therapies and gene editing technologies, offering approved treatments for conditions such as Duchenne muscular dystrophy. Its primary customers are patients with rare genetic disorders and the healthcare providers treating them.
Sarepta Therapeutics, Inc.
1980
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
2300000000
over-1b
ipo
NASDAQ:SRPT
nasdaq
Investors
Founders
James Summerton
Marwan Fawaz
Leadership
Douglas Ingram — CEO and President
Alex Lagadinos — Associate Director, Corporate Development
Peter Montague — Director Of Facilities
Kathy Behrens Wilsey — Director
Ian Estepan — President and Chief Operating Officer
Gary Charbonneau — SVP, GM , Head of Research & Early Development
William (Bill) F. Ciambrone — Executive Vice President, Technical Operations
Technology Stack
Products
SRP-9001 (delandistrogene moxeparvovec): An investigational gene therapy for treating ambulatory individuals with Duchenne muscular dystrophy by delivering a functional dystrophin gene.
SareptAssist: A patient support program providing personalized assistance with insurance, financial aid, treatment logistics, and ongoing education for individuals prescribed Sarepta therapies in the U.S.
RNA-targeted exon skipping therapies: Therapies that act on RNA to enable production of a shortened dystrophin protein by skipping mutated exons in genetic diseases like Duchenne muscular dystrophy.
Gene editing therapies: Therapies using gene editing technologies like CRISPR/Cas9 to excise mutated exons from genes to restore dystrophin expression in diseases such as Duchenne muscular dystrophy.
Funding rounds
POST_IPO_CONVERTIBLE · 700000000 · (2025-08-01T00:00:00)
POST_IPO_DEBT · 600000000 · (2025-02-01T00:00:00)
POST_IPO_EQUITY · 14150000 · (2023-12-01T00:00:00)